PRME
Prime Medicine, Inc.
Latest close $3.08 as of Aug 5, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 2 of 2 parsed filing(s)| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management CIK0001897612 | Dec 31, 2025 observed Feb 17, 2026 filed · 48d Schedule 13G amendment | Reported reduction | 6.0M -3.2M | 12.00% 0.00 pts | $3.47 | $3.31 | $3.08 |
| T. Rowe Price Investment Management CIK0001897612 | Sep 30, 2025 observed Nov 14, 2025 filed · 45d Initial Schedule 13G | Initial Schedule 13G | 9.2M | 12.00% | $5.54 | $3.37 | $3.08 |